The microbiome is increasingly recognized as a central regulator of cancer pathophysiology and a critical determinant of cancer immunotherapy efficacy across both solid and hematologic malignancies.
This initiative seeks to address a pressing need: helping clinicians translate complex, cross-disciplinary science into practical care, while shaping the next wave of research in this rapidly evolving area.
Evaluate
Evidence on the role of the microbiome in cancer care, with a focus on microbiome-modifying agents and their impact on treatment outcomes.
Identify
Areas of consensus and key gaps in clinical evidence and practice knowledge, and standards for evidence generated from new research.
Author
Clinically actionable consensus recommendations for healthcare practitioners, a research agenda to address the most urgent next questions, and standards for preclinical, translational, and clinical evidence.
Advocate
Changes to clinical practice and new research efforts in line with the recommendations.
